Thermo Fisher Scientific Inc. (TMO) recently completed the acquisition of Brahms AG for roughly $470 million (€330 million). Brahms AG is a leading provider of specialty in vitro diagnostic tests based on patented biomarkers for cardiovascular, sepsis and pulmonary diseases. The company also provides intensive care treatments and prenatal screening and is widely recognized for its flagship test, Procalcitonin (PCT).
The acquisition is expected to be accretive to Thermo Fisher’s earnings in 2010. The acquisition widens Thermo Fisher’s global reach and will increase its top-line. Brahms AG generated revenues of approximately $105 million (€75 million) in 2008. Thermo Fisher plans to integrate Brahms into its Analytical Technologies Segment and use the firm’s former headquarters in Germany as the European Center of Excellence for its clinical diagnostics business.
Thermo Fisher is a scientific instrument maker and a world leader in serving science. The company was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. in Nov 2006. Thermo Fisher Scientific serves its customers through two principal brands: Thermo Scientific and Fisher Scientific.
Thermo Scientific is the company’s technology brand that offers a complete range of high-end analytical, laboratory instruments, software, services, consumables and reagents to enable integrated laboratory workflow solutions. The Fisher Scientific brand offers a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education markets.
Thermo Fisher Scientific operates through two business segments – Analytical Technologies and Laboratory Products and Services. The company generated revenues of $10,498 million in fiscal 2008, an increase of approximately 8% year over year. Thermo Fisher’s main competitors are Agilent Technologies Inc. (A), Beckman Coulter Inc. (BEC), Becton Dickinson and Company (BDX), Danaher Corporation (DHR), etc.
Read the full analyst report on “TMO”
Read the full analyst report on “A”
Read the full analyst report on “BEC”
Read the full analyst report on “BDX”
Read the full analyst report on “DHR”
Zacks Investment Research
